Pub Date : 2024-04-27DOI: 10.1177/03008916241248007
Luca Agnelli, Andrea Villa, Fouziah Butt, Matteo Duca, Alessandro Guidi, Marcello Carapezza, Michele Addante, Gaetano Lenoci, Paul O’Regan, Laura Russo, Sara Cresta, Alessandra Castano, Elisabella Ebrahem, Sara Alfieri, Akshita Patil, Louise Carter, Caroline Dive, Filippo Guglielmo De Braud, Silvia Damian
The use of Digital Healthcare Products is leading to significant improvements in clinical practice. Herein, we discuss the development of PROACT 2.0 (Patient Reported Opinions About Clinical Tolerability v2.0), a novel open-source mobile and web application developed at Fondazione IRCCS Istituto Nazionale Tumori in Milan. It was developed in collaboration with The Christie, Manchester, in the context of work package 2 of the UpSMART Accelerator project, involving a consortium of referral cancer centers from the UK, Spain and Italy. PROACT 2.0 enhances communication between patients and healthcare providers in cancer clinical trials, allowing patients to report adverse events and side effects, and healthcare teams to collect valuable patient-reported outcome measures for treatment management. PROACT 2.0 supports text, audio, and video messaging, offering a secure, non-urgent communication channel that integrates with, or replaces, traditional methods. Its user-friendly and multilingual interface provides a new route for patient engagement and streamlines the handling of logistical information. Positive feedback from initial testing warrants future enhancements for broader applicability in cancer research and treatment.
{"title":"PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials","authors":"Luca Agnelli, Andrea Villa, Fouziah Butt, Matteo Duca, Alessandro Guidi, Marcello Carapezza, Michele Addante, Gaetano Lenoci, Paul O’Regan, Laura Russo, Sara Cresta, Alessandra Castano, Elisabella Ebrahem, Sara Alfieri, Akshita Patil, Louise Carter, Caroline Dive, Filippo Guglielmo De Braud, Silvia Damian","doi":"10.1177/03008916241248007","DOIUrl":"https://doi.org/10.1177/03008916241248007","url":null,"abstract":"The use of Digital Healthcare Products is leading to significant improvements in clinical practice. Herein, we discuss the development of PROACT 2.0 (Patient Reported Opinions About Clinical Tolerability v2.0), a novel open-source mobile and web application developed at Fondazione IRCCS Istituto Nazionale Tumori in Milan. It was developed in collaboration with The Christie, Manchester, in the context of work package 2 of the UpSMART Accelerator project, involving a consortium of referral cancer centers from the UK, Spain and Italy. PROACT 2.0 enhances communication between patients and healthcare providers in cancer clinical trials, allowing patients to report adverse events and side effects, and healthcare teams to collect valuable patient-reported outcome measures for treatment management. PROACT 2.0 supports text, audio, and video messaging, offering a secure, non-urgent communication channel that integrates with, or replaces, traditional methods. Its user-friendly and multilingual interface provides a new route for patient engagement and streamlines the handling of logistical information. Positive feedback from initial testing warrants future enhancements for broader applicability in cancer research and treatment.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140810609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-16DOI: 10.1177/03008916241246659
Rita Leporati, Daniela Miliziano, Teresa Beninato, Laura Mazzeo, Sara Manglaviti, Marta Brambilla, Mario Occhipinti, Arsela Prelaj, Claudia Proto, Giuseppe Lo Russo
Introduction:Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have been developed for the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-ALK-rearranged non-small cell lung cancer (NSCLC), with the newer generation agents brigatinib, alectinib and lorlatinib showing prolonged responses. With the increasing number of target therapies available, the optimal sequence is yet to be defined, as resistance profiles may evolve over time and in response to sequential ALK inhibitors. Therefore, ALK-targeted strategies may be personalized based upon the presence of specific ALK resistance mutations.Methods:Here, we report on the case of a patient who has been treated with a sequence of three ALK TKIs after receiving diagnosis of ALK-rearranged metastatic NSCLC in 2015 and gained further benefit upon lorlatinib rechallenge after the acquisition of the G1202R resistance mutation to second generation TKIs.Results and conclusion:In this case, the first ALK resistance mutation detected after progression on first line TKI, the I1171N, is a common resistance mutation after alectinib and confers sensitivity to brigatinib, that the patient received afterwards with a long-term disease stability. The second ALK resistance mutation detected after a chemotherapy interval, the G1202R, is the most common resistance mutation after second generation ALK TKIs and has been associated with sensitivity to third generation TKIs, such as lorlatinib. This case of a patient with EML4-ALK-rearranged NSCLC shows that sequential treatment with next-generation ALK TKIs, including rechallenge, can induce profound remissions, even in heavily pretreated patients, and that ALK-targeted strategies may be personalized by considering the presence of distinct ALK resistance mutations.
{"title":"Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs","authors":"Rita Leporati, Daniela Miliziano, Teresa Beninato, Laura Mazzeo, Sara Manglaviti, Marta Brambilla, Mario Occhipinti, Arsela Prelaj, Claudia Proto, Giuseppe Lo Russo","doi":"10.1177/03008916241246659","DOIUrl":"https://doi.org/10.1177/03008916241246659","url":null,"abstract":"Introduction:Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have been developed for the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-ALK-rearranged non-small cell lung cancer (NSCLC), with the newer generation agents brigatinib, alectinib and lorlatinib showing prolonged responses. With the increasing number of target therapies available, the optimal sequence is yet to be defined, as resistance profiles may evolve over time and in response to sequential ALK inhibitors. Therefore, ALK-targeted strategies may be personalized based upon the presence of specific ALK resistance mutations.Methods:Here, we report on the case of a patient who has been treated with a sequence of three ALK TKIs after receiving diagnosis of ALK-rearranged metastatic NSCLC in 2015 and gained further benefit upon lorlatinib rechallenge after the acquisition of the G1202R resistance mutation to second generation TKIs.Results and conclusion:In this case, the first ALK resistance mutation detected after progression on first line TKI, the I1171N, is a common resistance mutation after alectinib and confers sensitivity to brigatinib, that the patient received afterwards with a long-term disease stability. The second ALK resistance mutation detected after a chemotherapy interval, the G1202R, is the most common resistance mutation after second generation ALK TKIs and has been associated with sensitivity to third generation TKIs, such as lorlatinib. This case of a patient with EML4-ALK-rearranged NSCLC shows that sequential treatment with next-generation ALK TKIs, including rechallenge, can induce profound remissions, even in heavily pretreated patients, and that ALK-targeted strategies may be personalized by considering the presence of distinct ALK resistance mutations.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140611459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-12DOI: 10.1177/03008916241231035
Francesco Tucci, Arvydas Laurinavicius, Jakob Nikolas Kather, Catarina Eloy
Artificial intelligence (AI) applications in oncology are at the forefront of transforming healthcare during the Fourth Industrial Revolution, driven by the digital data explosion. This review provides an accessible introduction to the field of AI, presenting a concise yet structured overview of the foundations of AI, including expert systems, classical machine learning, and deep learning, along with their contextual application in clinical research and healthcare. We delve into the current applications of AI in oncology, with a particular focus on diagnostic imaging and pathology. Numerous AI tools have already received regulatory approval, and more are under active development, bringing clear benefits but not without challenges. We discuss the importance of data security, the need for transparent and interpretable models, and the ethical considerations that must guide AI development in healthcare. By providing a perspective on the opportunities and challenges, this review aims to inform and guide researchers, clinicians, and policymakers in the adoption of AI in oncology.
{"title":"The digital revolution in pathology: Towards a smarter approach to research and treatment","authors":"Francesco Tucci, Arvydas Laurinavicius, Jakob Nikolas Kather, Catarina Eloy","doi":"10.1177/03008916241231035","DOIUrl":"https://doi.org/10.1177/03008916241231035","url":null,"abstract":"Artificial intelligence (AI) applications in oncology are at the forefront of transforming healthcare during the Fourth Industrial Revolution, driven by the digital data explosion. This review provides an accessible introduction to the field of AI, presenting a concise yet structured overview of the foundations of AI, including expert systems, classical machine learning, and deep learning, along with their contextual application in clinical research and healthcare. We delve into the current applications of AI in oncology, with a particular focus on diagnostic imaging and pathology. Numerous AI tools have already received regulatory approval, and more are under active development, bringing clear benefits but not without challenges. We discuss the importance of data security, the need for transparent and interpretable models, and the ethical considerations that must guide AI development in healthcare. By providing a perspective on the opportunities and challenges, this review aims to inform and guide researchers, clinicians, and policymakers in the adoption of AI in oncology.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140564067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-09DOI: 10.1177/03008916241245005
Andrea Ferrari, Teresa Perillo, Giuseppe Maria Milano, Matteo Silva, Chiara Rutigliano, Andrea Salvo, Virginia Livellara, Massimo Conte, Luca Coccoli, Elena Amore, Marta Pierobon, Francesco Vietina, Elena Pagani Bagliacca, Marco Spinelli, Maria Speranza Massei, Valentina Massetti, Elena Legnani, Ilaria Puglisi, Giulia Zucchetti, Paola Quarello
This article describes the oncology programs developed in Italy for adolescents and young adults with cancer, with a specific focus on the local projects created in pediatric oncology centers. A common feature of such projects is the emphasis on creative and artistic activities and laboratories (involving music, photography, novel writing, fashion design, and so on) designed to give young patients innovative means of expression.This article highlights the amazing powers of adolescents involved in these projects: the power to produce beautiful things in a place that is not normally associated with the idea of beauty; the power to make their doctors smile and grasp the profound sense of life; the power to make hospitals become places for producing culture.
{"title":"The power of art and the powers of adolescents with cancer: Age-specific projects at Italian pediatric oncology centers","authors":"Andrea Ferrari, Teresa Perillo, Giuseppe Maria Milano, Matteo Silva, Chiara Rutigliano, Andrea Salvo, Virginia Livellara, Massimo Conte, Luca Coccoli, Elena Amore, Marta Pierobon, Francesco Vietina, Elena Pagani Bagliacca, Marco Spinelli, Maria Speranza Massei, Valentina Massetti, Elena Legnani, Ilaria Puglisi, Giulia Zucchetti, Paola Quarello","doi":"10.1177/03008916241245005","DOIUrl":"https://doi.org/10.1177/03008916241245005","url":null,"abstract":"This article describes the oncology programs developed in Italy for adolescents and young adults with cancer, with a specific focus on the local projects created in pediatric oncology centers. A common feature of such projects is the emphasis on creative and artistic activities and laboratories (involving music, photography, novel writing, fashion design, and so on) designed to give young patients innovative means of expression.This article highlights the amazing powers of adolescents involved in these projects: the power to produce beautiful things in a place that is not normally associated with the idea of beauty; the power to make their doctors smile and grasp the profound sense of life; the power to make hospitals become places for producing culture.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"312 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140563931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-01DOI: 10.1177/03008916221114500
C. Oliva, S. Miraglia, A. Comandone, E. Trinchero
Background: Outpatient and Day Hospital activities represent the main commitment for a Medical Oncology. Part of the relationship with outpatients is necessarily maintained by telephone. We wanted to quantify the commitment represented by managing patient calls in our daily practice. Material(s) and Method(s): From 1/1/21 to 30/6/21 we recorded the telephone movement that took place at our Oncological Day Hospital (DH). The DH activity involves 9 doctors and in 2021. 946 patients were followed for chemotherapy (CT) and 7298 courses of CT were administered. Phone calls received from 8:00 to 16:00 were recorded by the administrative staff in a specially built database and then were routed to each doctor who proceeded to recall the patient within 24 hours. Result(s): We recorded 2901 phone calls divided according to the following arguments: 757 (26.1%) concerned treatment toxicity, 622 (21.4%) symptoms related to disease, 520 (17.9%) concerned organizational issues, 466 (16.1%) were asked for explanations about prescribed therapies, 327 (11.3%) were asked for evaluation of new exams, 209 (7.2%) concerned Covid vaccines. We then analyzed the database by quantifying the number of telephone accesses for each individual patient and we noticed that, 55 patients made more than 10 phone calls, 39 patients made between 8 and 10 phone calls, 119 patients between 5 and 7 phone calls. This group of 213 patients (22.5% of the total) was responsible for 1762 phone calls (60.1%). According to the Literature, the average duration of a telephone call varies from 9 to 12 minutes, therefore the weight of the Medical activity carried out by telephone is approximately 4.4-5.8 hours daily. Furthermore, each phone call (about 29 a day), as an interruption of scheduled activities, is a potential source of distraction and therefore of error for every professionist. These data, however important, are certainly underestimated because they don't take into account the telephone calls received directly to the Physicians (mobile, instant messaging, e-mail) that were not recorded. Conclusion(s): In our Oncology Day Hospital, taking care of patient calls takes up to 4.4-5.8 hours daily and is a significant source of interruption of scheduled activities. According to our data a small group of patients is responsible for a large part of phone calls. To reduce the effort required by patient phone calls, it is necessary to early identify this subgroup and make it subject of a monitoring active program.
{"title":"AIOM Abstract","authors":"C. Oliva, S. Miraglia, A. Comandone, E. Trinchero","doi":"10.1177/03008916221114500","DOIUrl":"https://doi.org/10.1177/03008916221114500","url":null,"abstract":"Background: Outpatient and Day Hospital activities represent the main commitment for a Medical Oncology. Part of the relationship with outpatients is necessarily maintained by telephone. We wanted to quantify the commitment represented by managing patient calls in our daily practice. Material(s) and Method(s): From 1/1/21 to 30/6/21 we recorded the telephone movement that took place at our Oncological Day Hospital (DH). The DH activity involves 9 doctors and in 2021. 946 patients were followed for chemotherapy (CT) and 7298 courses of CT were administered. Phone calls received from 8:00 to 16:00 were recorded by the administrative staff in a specially built database and then were routed to each doctor who proceeded to recall the patient within 24 hours. Result(s): We recorded 2901 phone calls divided according to the following arguments: 757 (26.1%) concerned treatment toxicity, 622 (21.4%) symptoms related to disease, 520 (17.9%) concerned organizational issues, 466 (16.1%) were asked for explanations about prescribed therapies, 327 (11.3%) were asked for evaluation of new exams, 209 (7.2%) concerned Covid vaccines. We then analyzed the database by quantifying the number of telephone accesses for each individual patient and we noticed that, 55 patients made more than 10 phone calls, 39 patients made between 8 and 10 phone calls, 119 patients between 5 and 7 phone calls. This group of 213 patients (22.5% of the total) was responsible for 1762 phone calls (60.1%). According to the Literature, the average duration of a telephone call varies from 9 to 12 minutes, therefore the weight of the Medical activity carried out by telephone is approximately 4.4-5.8 hours daily. Furthermore, each phone call (about 29 a day), as an interruption of scheduled activities, is a potential source of distraction and therefore of error for every professionist. These data, however important, are certainly underestimated because they don't take into account the telephone calls received directly to the Physicians (mobile, instant messaging, e-mail) that were not recorded. Conclusion(s): In our Oncology Day Hospital, taking care of patient calls takes up to 4.4-5.8 hours daily and is a significant source of interruption of scheduled activities. According to our data a small group of patients is responsible for a large part of phone calls. To reduce the effort required by patient phone calls, it is necessary to early identify this subgroup and make it subject of a monitoring active program.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"128 1","pages":"1 - 194"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77458366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1177/03008916221115478
Book 2 Tumori Journal 108(3S) Conclusion: Obstructive jaundice is more common among males and cancer head of pancreas is the commonest malignancy.US, ERCP and CT-Scan are important diagnostic modalities for evaluation of patient with obstructive jaundice with ERCP having the additional advantage of being therapeutic as well.
{"title":"IGILUC abstracts","authors":"","doi":"10.1177/03008916221115478","DOIUrl":"https://doi.org/10.1177/03008916221115478","url":null,"abstract":"Book 2 Tumori Journal 108(3S) Conclusion: Obstructive jaundice is more common among males and cancer head of pancreas is the commonest malignancy.US, ERCP and CT-Scan are important diagnostic modalities for evaluation of patient with obstructive jaundice with ERCP having the additional advantage of being therapeutic as well.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"33 1","pages":"1 - 10"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84609395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：